STACKDSTACKDResearch
Sign up

Compound library

Peptides

Deep profiles for diligence, not product pages. Filter by goal or open any profile for mechanism, evidence, and citations.

45 compounds catalogued

Filter by goal

AllRecoveryFat lossMuscle / GH axisSkin / repairSleep / recovery adjunctMetabolicCognitive / nootropicMood / anxietyNeuroprotectionImmune supportGut healthLongevity / agingSexual health

Showing 4 peptides tagged Neuroprotection.

Semax

Limited human data

A synthetic heptapeptide analogue of ACTH(4-10), registered as a prescription drug in Russia for ischemic stroke and optic nerve conditions. One of the most frequently discussed "nootropic peptides" in biohacking communities, alongside Selank.

Cognitive / nootropic · Neuroprotection

Cerebrolysin

Limited human data

A mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain proteins, approved in several countries for stroke and traumatic brain injury recovery. Distinct from single-sequence research peptides: it's a multi-component biological preparation.

Cognitive / nootropic · Neuroprotection

ARA-290 (Cibinetide)

Limited human data

An 11-amino-acid peptide engineered from a non-erythropoietic region of erythropoietin, designed to activate tissue-repair signaling without stimulating red blood cell production. Studied in phase 2 human trials for small-fiber neuropathy, one of the more clinically tested "tissue protective" peptides.

Recovery · Neuroprotection

Dihexa

Emerging

A small, orally active molecule derived from angiotensin IV, developed as a potential cognition-enhancing compound by potentiating HGF/c-Met signaling involved in synapse formation. Studied only in animal models; its foundational 2013 paper has since received a formal journal Notice of Concern, adding an important caveat to an already early-stage evidence base.

Cognitive / nootropic · Neuroprotection

Evidence labels

  • EmergingMostly preclinical or early signals; human athletic data is thin.
  • Limited human dataSome human pharmacology or small studies; outcomes for fitness use remain limited.
  • Stronger clinical signalSupported by larger clinical trials in defined medical populations.

Anodized by evidence strength: blue = stronger clinical/human data, violet = limited human data or mechanism, steel = emerging/anecdotal, and amber = an in-house STACKD summary.